Advertisement
12/04/2022

Aucta receives FDA OK for generic Perforomist

Generic Perforomist is used to control the symptoms of COPD in adults with COPD.
Sandra Levy
Senior Editor
Sandra Levy profile picture

Aucta has obtained the Food and Drug Administration’s nod for formoterol fumarate inhalation solution, which is the generic of Mylan’s Perforomist.

The medication is a long-acting beta2-adrenergic agonist used to control the symptoms of COPD in adults with COPD.

[Read more: Oakrum, Aucta gain FDA nod for generic Jadenu]

"We are pleased to have our third Aucta Pharmaceuticals-developed product approved for the U.S. market," said Brian Zorn, chief commercial officer of Aucta. "This marks the launch of our new commercial infrastructure to commercialize this and future products in the United States."

Formoterol fumarate inhalation solution had a market value exceeding $268 million for the 12-month period ending September 2022, according to IQVIA.

    Advertisement
    Advertisement